Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An infection caused by Hantaviruses. It manifests with flu-like symptoms but it rapidly progresses to life-threatening respiratory problems.
Biomarker and diagnostic research for hantavirus pulmonary syndrome has been reported in the published literature.
2 clinical trials registered, 1 recruiting. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
146 publications have been identified in PubMed for hantavirus pulmonary syndrome. Research spans Epidemiology / Natural History (31%), Basic Science / Preclinical (25%), and Review / Meta-Analysis (15%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 45 |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 1:12 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Laboratory research | 36 | 25% |
Research summaries | 22 | 15% |
Patient case studies | 13 | 9% |
Other research | 11 | 8% |
Testing and diagnosis research | 9 | 6% |
New treatment approaches | 6 | 4% |
Clinical study results | 4 | 3% |
López-Camacho C (2026). [PMID: 42120482](https://pubmed.ncbi.nlm.nih.gov/42120482/). *Nature*. [Case Report / Case Series]
Oliveira FMG (2026). [PMID: 41983792](https://pubmed.ncbi.nlm.nih.gov/41983792/). *Rev Inst Med Trop Sao Paulo*. [Review / Meta-Analysis]
Hodgens A (2026). [PMID: 32644403](https://pubmed.ncbi.nlm.nih.gov/32644403/). *Unknown Journal*. [Epidemiology / Natural History]
Chandy S (2026). [PMID: 41437794](https://pubmed.ncbi.nlm.nih.gov/41437794/). *Microbiology and immunology*. [Diagnostic / Biomarker]
Tortosa F (2026). [PMID: 42235569](https://pubmed.ncbi.nlm.nih.gov/42235569/). *Lancet Infect Dis*. [Case Report / Case Series]
Rickard G (2026). [PMID: 42116630](https://pubmed.ncbi.nlm.nih.gov/42116630/). *Emerg Infect Dis*. [Basic Science / Preclinical]
Nishiura H (2026). [PMID: 42232640](https://pubmed.ncbi.nlm.nih.gov/42232640/). *New Microbes New Infect*. [Other]
Kupferschmidt K (2026). [PMID: 42133774](https://pubmed.ncbi.nlm.nih.gov/42133774/). *Science*. [Epidemiology / Natural History]
Velavan TP (2026). [PMID: 42107872](https://pubmed.ncbi.nlm.nih.gov/42107872/). *Int J Infect Dis*. [Epidemiology / Natural History]
Islam MS (2026). [PMID: 42140222](https://pubmed.ncbi.nlm.nih.gov/42140222/). *Lancet*. [Other]
AI-curated news mentioning hantavirus pulmonary syndrome
Updated Jun 10, 2026
The CDC is seeking public comment on a proposed information collection project related to monitoring travelers for Andes hantavirus. This initiative aims to reduce public burden while enhancing data utility.
Eli Lilly has secured four new deals in the past week, focusing on the vaccine space and highlighting its advancements in obesity treatment with promising results for its next-gen weight loss drug. Meanwhile, Moderna's stock has risen due to increased interest surrounding hantavirus concerns.
Moderna's stock gains traction as concerns over hantavirus resurface, highlighting the company's infectious disease platform. Analysts suggest this could enhance Moderna's reputation during a politically charged environment for vaccine manufacturers.
EMA is monitoring a hantavirus outbreak associated with a cruise ship, collaborating with EU bodies to address the situation. The outbreak involves the Andes hantavirus, which poses public health concerns.